{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:00:41Z","timestamp":1792083641374,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1950-7","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T08:03:19Z","timestamp":1562572999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-3559","authenticated-orcid":false,"given":"Gabriella","family":"Giancane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Muratore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Marzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Quilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen Serrano","family":"Benavente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bagnasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Civino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Quartulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Consolaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"key":"1950_CR1","first-page":"186S","volume":"64","author":"DJ Lovell","year":"1997","unstructured":"Lovell DJ. Ten years of experience with methotrexate. Past, present and future. Rev Rhum Engl Ed. 1997;64(10Suppl:186S\u20138S.","journal-title":"Rev Rhum Engl Ed"},{"key":"1950_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nrrheum.2013.105","volume":"9","author":"DJ Lovell","year":"2013","unstructured":"Lovell DJ, Ruperto N, Giannini EH, Martini A. Advances from clinical trials in juvenile idiopathic arthritis. Nat Rev Rheumatol. 2013;9:557\u201363.","journal-title":"Nat Rev Rheumatol"},{"key":"1950_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/art.1780290616","volume":"29","author":"H Truckenbrodt","year":"1986","unstructured":"Truckenbrodt H, Ha R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum. 1986;29:801\u20137.","journal-title":"Arthritis Rheum"},{"key":"1950_CR4","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","volume":"326","author":"EH Giannini","year":"1992","unstructured":"Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JTZL. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children\u2019s Study Group. N Engl J Med. 1992;326:1043\u20139.","journal-title":"N Engl J Med"},{"key":"1950_CR5","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/art.20288","volume":"50","author":"N Ruperto","year":"2004","unstructured":"Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004;50:2191\u2013201.","journal-title":"Arthritis Rheum"},{"key":"1950_CR6","first-page":"867","volume":"17","author":"P Malleson","year":"1990","unstructured":"Malleson P, Petty R. Remodelling the pyramid--a pediatric prospective. J Rheumatol. 1990;17:867\u20138.","journal-title":"J Rheumatol"},{"key":"1950_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/00002281-199809000-00013","volume":"10","author":"PB Dent","year":"1998","unstructured":"Dent PB, Walker N. Intra-articular corticosteroids in the treatment of juvenile rheumatoid arthritis. Curr Opin Rheumatol. 1998;10:475\u201380.","journal-title":"Curr Opin Rheumatol"},{"key":"1950_CR8","unstructured":"Scott C, Meiorin S, Filocamo G, et al. A reappraisal of intra-articular corticosteroid therapy in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2010;28:774-81."},{"key":"1950_CR9","first-page":"1989","volume":"29","author":"K Oen","year":"2002","unstructured":"Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol. 2002;29:1989\u201399.","journal-title":"J Rheumatol"},{"key":"1950_CR10","first-page":"394","volume":"30","author":"SL Bowyer","year":"2003","unstructured":"Bowyer SL, Roettcher PA, Higgins GC, Adams B, Myers LK, Wallace C, Rennebohm R, Moore TL, Pepmueller PH, Spencer C, Wagner-Weiner L, Rabinovich E, Passo M, Lovell DJ, McCurdy D, Zemel L, Schikler KN, Szer I, Kurtin PLC. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol. 2003;30:394\u2013400.","journal-title":"J Rheumatol"},{"key":"1950_CR11","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.24202","volume":"59","author":"N Solari","year":"2008","unstructured":"Solari N, Viola S, Pistorio A, et al. Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. Arthritis Care Res. 2008;59:1571\u20139.","journal-title":"Arthritis Care Res"},{"key":"1950_CR12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with Polyarticular juvenile rheumatoid Arthritis. N Engl J Med. 2000;342:763\u20139.","journal-title":"N Engl J Med"},{"key":"1950_CR13","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096\u2013106.","journal-title":"Arthritis Rheum"},{"key":"1950_CR14","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810\u201320.","journal-title":"N Engl J Med"},{"issue":"1","key":"1950_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","volume":"77","author":"Hermine I Brunner","year":"2017","unstructured":"Brunner HI, Ruperto N, Tzaribachev N, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2017. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-210456\n                    \n                  .","journal-title":"Annals of the Rheumatic Diseases"},{"key":"1950_CR16","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online], \n                    http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01230827\n                    \n                   (2013)."},{"key":"1950_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372:383\u201391.","journal-title":"Lancet."},{"key":"1950_CR18","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998\u20131006.","journal-title":"Lancet."},{"key":"1950_CR19","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385\u201395.","journal-title":"N Engl J Med"},{"key":"1950_CR20","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747\u201354.","journal-title":"Ann Rheum Dis"},{"key":"1950_CR21","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of Canakinumab in systemic juvenile idiopathic Arthritis. N Engl J Med. 2012;367:2396\u2013406.","journal-title":"N Engl J Med"},{"issue":"9","key":"1950_CR22","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/art.38042","volume":"65","author":"DJ Lovell","year":"2013","unstructured":"Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65(9):2486\u201396.","journal-title":"Arthritis Rheum"},{"key":"1950_CR23","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/art.38699","volume":"66","author":"NT Ilowite","year":"2014","unstructured":"Ilowite NT, Prather K, Lokhnygina Y, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol (Hoboken, NJ). 2014;66:2570\u20139.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)."},{"key":"1950_CR24","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1002\/art.27682","volume":"62","author":"EH Giannini","year":"2010","unstructured":"Giannini EH, Ilowite NT, Lovell DJ, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2010;62:3259\u201364.","journal-title":"Arthritis Rheum"},{"key":"1950_CR25","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/annrheumdis-2012-202310","volume":"72","author":"S Yokota","year":"2013","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto NKT. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan. Ann Rheum Dis. 2013;72:627\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1950_CR26","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1136\/annrheumdis-2018-213150","volume":"77","author":"Nicolino Ruperto","year":"2018","unstructured":"Ruperto N, Brunner HI, Quartier P, et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis. 2018;77:1710-19.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"1950_CR27","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(17)30065-X","volume":"389","author":"A Ravelli","year":"2017","unstructured":"Ravelli A, Dav\u00ec S, Bracciolini G, Pistorio A, Consolaro A, van Dijkhuizen EH, Lattanzi B, Filocamo G, Verazza S, Gerloni V, Gattinara M, Pontikaki I, Insalaco A, De Benedetti F, Civino A, Presta G, Breda L, Marzetti V, Pastore S, Magni- AIPRSG. Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. Lancet. 2017;389:909\u201316.","journal-title":"Lancet."},{"key":"1950_CR28","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/ard.2010.143347","volume":"70","author":"P Tynjala","year":"2011","unstructured":"Tynjala P, Vahasalo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70:1605\u201312.","journal-title":"Ann Rheum Dis"},{"key":"1950_CR29","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"CA Wallace","year":"2012","unstructured":"Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012-2021;64:2012.","journal-title":"Arthritis Rheum"},{"key":"1950_CR30","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol (Hoboken, NJ). 2014;66:1034\u201343.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"1950_CR31","first-page":"819","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, Akikusa JD, Al-Mayouf SM, Ant\u00f3n J, Avcin T, Berard RA, Beresford MW, Burgos-Vargas R, Cimaz R, De Benedetti F, Demirkaya E, Foell D, Itoh Y, Lahdenne PSJ. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77:819\u201328.","journal-title":"Ann Rheum Dis"},{"key":"1950_CR32","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1136\/annrheumdis-2014-205372","volume":"74","author":"J Guzman","year":"2015","unstructured":"Guzman J, Oen K, Tucker LB, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-out cohort. Ann Rheum Dis. 2015;74:1854\u201360.","journal-title":"Ann Rheum Dis"},{"key":"1950_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12969-016-0126-0","volume":"14","author":"S Verazza","year":"2016","unstructured":"Verazza S, Dav\u00ec S, Consolaro A, et al. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatr Rheumatol. 2016;14:68.","journal-title":"Pediatr Rheumatol"},{"key":"1950_CR34","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/acr.22477","volume":"67","author":"CY Chang","year":"2015","unstructured":"Chang CY, Meyer RML, Reiff AO. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Arthritis Care Res (Hoboken). 2015;67:658\u201366.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1950_CR35","first-page":"1","volume":"6736","author":"Wulffraat","year":"2017","unstructured":"Wulffraat. The value of old drugs for juvenile idiopathic arthritis. Lancet (London, England). 2017;6736:1\u20132.","journal-title":"Lancet (London, England)"},{"key":"1950_CR36","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"key":"1950_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/ard.56.3.197","volume":"56","author":"A Ravelli","year":"1997","unstructured":"Ravelli A, Viola S, Ruperto N, Corsi B, Ballardini G, Martini A. Correlation between conventional disease activity measures in juvenile chronic arthritis. Ann Rheum Dis. 1997;56:197\u2013200.","journal-title":"Ann Rheum Dis"},{"key":"1950_CR38","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658\u201366.","journal-title":"Arthritis Rheum"},{"key":"1950_CR39","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1136\/annrheumdis-2012-202031","volume":"72","author":"F McErlane","year":"2013","unstructured":"McErlane F, Beresford MW, Baildam EM, et al. Validity of a three-variable juvenile arthritis disease activity score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2013;72:1983\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1950_CR40","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1002\/acr.22393","volume":"66","author":"A Consolaro","year":"2014","unstructured":"Consolaro A, Negro G, Chiara Gallo M, et al. Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. Arthritis Care Res (Hoboken). 2014;66:1703\u20139.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"1950_CR41","first-page":"2290","volume":"31","author":"CA Wallace","year":"2004","unstructured":"Wallace CA, Ruperto N, Giannini E, Arthritis C. Preliminary criteria for clinical remission for select categories of juvenile idiopathic Arthritis re er d. J Rheumatol. 2004;31:2290\u20134.","journal-title":"J Rheumatol"},{"key":"1950_CR42","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1002\/art.34373","volume":"64","author":"A Consolaro","year":"2012","unstructured":"Consolaro A, Bracciolini G, Ruperto N, et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum. 2012;64:2366\u201374.","journal-title":"Arthritis Rheum"},{"key":"1950_CR43","first-page":"S126","volume":"32","author":"A Consolaro","year":"2014","unstructured":"Consolaro A, Schiappapietra B, Dalpr\u00e0 S, Calandra S, Martini A, Ravelli A. Optimisation of disease assessments in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2014;32:S126\u201330.","journal-title":"Clin Exp Rheumatol"},{"key":"1950_CR44","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1002\/art.21119","volume":"52","author":"S Viola","year":"2005","unstructured":"Viola S, Felici E, Magni-Manzoni S, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:2092\u2013102.","journal-title":"Arthritis Rheum"},{"key":"1950_CR45","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3899\/jrheum.131503","volume":"41","author":"CA Wallace","year":"2014","unstructured":"Wallace CA, Giannini EH, Spalding SJ, et al. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol. 2014;41:1163\u201370.","journal-title":"J Rheumatol"},{"key":"1950_CR46","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1136\/annrheumdis-2014-207164","volume":"75","author":"J Guzman","year":"2016","unstructured":"Guzman J, Oen K, Huber AM, et al. The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Ann Rheum Dis. 2016;75:1092\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1950_CR47","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1136\/annrheumdis-2016-210511","volume":"76","author":"SJW Shoop-Worrall","year":"2017","unstructured":"Shoop-Worrall SJW, Verstappen SMM, Baildam E, et al. How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition. Ann Rheum Dis. 2017;76:1381\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1950_CR48","doi-asserted-by":"publisher","first-page":"e000074","DOI":"10.1136\/rmdopen-2015-000074","volume":"1","author":"Claudia Sengler","year":"2015","unstructured":"Sengler C, Klotsche J, Niewerth M, et al. The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort. RMD Open. 2015 8;1(1):e000074.","journal-title":"RMD Open"},{"key":"1950_CR49","first-page":"1285","volume":"51","author":"S Boiu","year":"2012","unstructured":"Boiu S, Marniga E, Bader-Meunier B, et al. Functional status in severe juvenile idiopathic arthritis in the biologic treatment era: an assessment in a French paediatric rheumatology referral centre. Rheumatol (United Kingdom). 2012;51:1285\u201392.","journal-title":"Rheumatol (United Kingdom)"},{"key":"1950_CR50","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/01.bor.0000240360.24465.4c","volume":"18","author":"B Arabshahi","year":"2006","unstructured":"Arabshahi B, Cron RQ. Temporomandibular joint arthritis in juvenile idiopathic arthritis: the forgotten joint. Curr Opin Rheumatol. 2006;18:490\u20135.","journal-title":"Curr Opin Rheumatol"},{"key":"1950_CR51","first-page":"1805","volume":"32","author":"E Felici","year":"2005","unstructured":"Felici E, Novarini C, Magni-Manzoni S, et al. Course of joint disease in patients with antinuclear antibody-positive juvenile idiopathic arthritis. J Rheumatol. 2005;32:1805\u201310.","journal-title":"J Rheumatol"},{"key":"1950_CR52","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1093\/rheumatology\/ker165","volume":"50","author":"S Lanni","year":"2011","unstructured":"Lanni S, Bertamino M, Consolaro A, et al. Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis. Rheumatology (Oxford). 2011;50:1627\u201334.","journal-title":"Rheumatology (Oxford)"},{"key":"1950_CR53","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1002\/1529-0131(199911)42:11<2330::AID-ANR11>3.0.CO;2-B","volume":"42","author":"DD Sherry","year":"1999","unstructured":"Sherry DD, Stein LD, Reed AM, et al. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum. 1999;42:2330\u20134.","journal-title":"Arthritis Rheum"},{"key":"1950_CR54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1546-0096-10-39","volume":"10","author":"A Consolaro","year":"2012","unstructured":"Consolaro A, Ruperto N, Filocamo G, et al. Seeking insights into the EPidemiology, treatment and outcome of childhood arthritis through a multinational collaborative effort: introduction of the EPOCA study. Pediatr Rheumatol Online J. 2012;10:39.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1950_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-018-1588-x","volume":"20","author":"M Listing","year":"2018","unstructured":"Listing M, M\u00f6nkem\u00f6ller K, Liedmann I, et al. The majority of patients with newly diagnosed juvenile idiopathic arthritis achieve a health-related quality of life that is similar to that of healthy peers: results of the German multicenter inception cohort (ICON). Arthritis Res Ther. 2018;20:1\u201312.","journal-title":"Arthritis Res Ther"},{"key":"1950_CR56","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/acr.20497","volume":"63","author":"CA Wallace","year":"2011","unstructured":"Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. 2011;63:929\u201336.","journal-title":"Arthritis Care Res"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1950-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1950-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1950-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T19:23:46Z","timestamp":1594063426000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1950-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1950"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1950-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736170917.793582473","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,8]]},"assertion":[{"value":"14 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee of the Istituto G. Gaslini, Genoa, Italy. All parents\/guardians or patients (as appropriate) provided informed consent to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AR has received grant support and\/or speaking or consultant fees from Angelini, AbbVie, Bristol-Myers Squibb, Johnson & Johnson, Novartis, Pfizer, Reckitt Benkiser, and Roche; AC reports personal fees from Abbvie and non-financial support from Pfizer; GG, VM, VM, NQ, BSB, AA, AC, and LQ declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}